

SUVEN Life Sciences Ltd



News Release

Suven's yearly revenues increase by 38%

PAT up by 33%; R&D spend at 24% of Revenue.

HYDERABAD, INDIA (Apl' 26, 2007) – SUVEN LIFE Science's Board of Directors meeting held today in Hyderabad announced the results that **the revenue increased by 38% to Rs. 11458 lacs** for the year ending Mar' 2007 compared to Rs. 8300 lacs for the previous year. **PAT up by 33%** from Rs. 846 lacs to Rs. 1122 lacs. **Exports up by 38%** from Rs. 6369 lacs to Rs. 8787 lacs.

For the 4th Quarter ending Mar' 2007, the **revenues up by 47%** to Rs.2873 lacs compared to the corresponding quarter of the previous year of Rs.1956 lacs.. The **PAT is up by 24%** from Rs.226 lacs to Rs.281 lacs.

Suven's major thrust on **innovative R&D in Drug Discovery** continues with a total expenditure (revenue&capital) of Rs 2758 lacs recording about **24% of revenue** for the year.

Suven Life Sciences is a Hyderabad based Life Sciences Company, a Collaborative Research Partner (CRP)in Drug Discovery for global pharma major is a pioneer in Contract Research and Manufacturing Services (CRAMS) since 1995 and Drug Discovery Development Support Services (DDDSS) since 2005. Suven has been involved in development of path breaking technologies for global pharma companies for more than a decade. Suven was awarded "Partner of Choice in Drug Discovery for CNS" by Frost & Sullivan in 2005.

A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven's commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas. Suven has R&D strength of more than 190 professionals with the state of the art infrastructure for Drug Discovery and development activities with 30 clinical research professionals and the front end project management services from New Jersey, USA. For more information on Suven, please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;